News

Noticias

European Commission grants Marketing Authorisation for eslicarbazepine acetate as once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy

Bial and Eisai announce that the European Medicines Agency (EMA) has approved eslicarbazepine acetate for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy. It is already indicated in Europe as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. “We are pleased that adults with partial-onset epilepsy across Europe are now able to benefit from a once-daily monotherapy option that is simple to use, which may optimise their adherence,” comments António Portela, CEO of Bial. “Bial has an ongoing commitment to all people living with epilepsy and we look forward to continuing to work with the epilepsy community to bring this new indication to patients.”

Read

BIAL Award 2016 winners

320.000 euros to 4 different works on rheumatic diseases, diabetic foot, cancer and osteoporosis in the 17th edition of the BIAL Award • BIAL Merit Award in Medical Sciences distinguishes Jaime Cunha Branco and co-authors for their work “EpiReumaPt – Epidemiological Study of Rheumatic Diseases in Portugal” • BIAL Award in Clinical Medicine distinguishes the work "Pé Di@bético (Di@betic Foot) – solutions to a major problem", authored by Maria de Jesus Dantas

Read

Let’s #UniteforParkinsons?

EPDA CAMPAIGN TO CELEBRATE WORLD PARKINSON’S DAY – APRIL 11 EPDA (European Parkinson Disease Association) launched a campaign on World Parkinson’s Day and BIAL is united for Parkinson. 2017 marks 200 years since Parkinson’s was recognised as a health condition, so BIAL will be focused on this condition and on people living with Parkinson, as it is one of its research areas. #UniteforParkinsons

Read

“ME AT MY BEST” - People with Parkinson's are "much more than their disease"

BIAL LAUNCHES INTERNATIONAL CAMPAIGN FOR WORLD PARKINSON'S DAY: APRIL 11 2017 Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush. This is how it feels to live with Parkinson’s, a real challenge for the 10 million of people diagnosed with Parkinson’s disease around the world.

Read

BIAL is the third portuguese company which granted more patents in 2016

THE EUROPEAN PATENT OFFICE (EPO) GRANTS RECORD NUMBER OF EUROPEAN PATENTS LAST YEAR EPO published over 95 000 granted patents last year, 40% more than in 2015 and a new high mark in its history. In Portugal, BIAL is the third company which granted more patents last year. R&D is one of BIAL’s strategic area.

Read

BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

OPICAPONE APPROVED IN EUROPE IN JUNE 2016 BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. Opicapone is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.

Read

BIAL sells allergic immunotherapy business

BIAL has reached an agreement with the German company Roxall to sell its allergic immunotherapy business unit, known as BIAL Aristegui, dedicated to the development, production and commercialization of anti-allergic vaccines and diagnostic tests. This operation includes the commercial areas dedicated to allergology in Spain, Portugal and Italy, which represented 7% of BIAL's global turnover in 2016, as well as the R&D and industrial unit located in Bilbao, involving around 100 employees who will become integrated into Roxall.

Read

Portugal’s Prime Minister and the Ministers of Health and Economy visited BIAL

The visit to the Research and Development Center, in Trofa, took place in the scope of an investment contract. BIAL has just signed an investment contract with the Portuguese Government of over €37 Mio, to be carried out until December 2018. The Prime Minister, António Costa, and the Ministers of Health and Economy attended the contract signature ceremony after visiting BIAL’s R&D Department.

Read